-transparent.png){kind=logo}
A series of quinazolines has been prepared and evaluated for its ability to inhibit cyclic AMP phosphodiesterase type 3, type 4A, 4B and 4D. The most potent inhibitors showed IC50 values in the nanomolar range for type 3 and type 4 isoforms and bind with high affinity to the [3H]rolipram binding site. These quinazolines represent a new family of potent mixed PDE 3/4 inhibitors and are expected to have a therapeutic potential.
Related Publications
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
January 1985,
Journal of medicinal chemistry,
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
April 2004,
European journal of pharmacology,
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
March 2018,
Journal of the American Academy of Dermatology,
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
July 2001,
Lancet (London, England),
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
October 2006,
The Journal of pharmacology and experimental therapeutics,
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
January 2002,
Biology of reproduction,
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
March 2011,
Revista clinica espanola,
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
February 1948,
Journal of the American Chemical Society,
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
May 1998,
Circulation research,
B Charpiot, and
J Brun, and
I Donze, and
R Naef, and
M Stefani, and
T Mueller
October 2004,
Bioorganic & medicinal chemistry,
